Advanced Gastrointestinal Endoscopic Imaging
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To develop new methods to detect malignant and premalignant conditions of the gastrointestinal tract.
| Condition | Intervention |
|---|---|
|
Gastrointestinal Diseases Malignant Neoplasm of Stomach Gastrointestinal Stromal Tumors |
Device: Dual axis endoscopic microscope Device: wide field fluorescence system Device: CellVizio Drug: fluorescent Peptide Drug: fluorescein Drug: indocyanine green |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | Advanced Gastrointestinal Endoscopic Imaging |
- Detection of neoplasia [ Time Frame: 5 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 500 |
| Study Start Date: | June 2009 |
| Estimated Study Completion Date: | June 2014 |
| Estimated Primary Completion Date: | June 2014 (Final data collection date for primary outcome measure) |
-
Device: Dual axis endoscopic microscope
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:patients be at least 18 years of age,
Either genders
All ethnic backgrounds will be considered.
Patients who are scheduled for endoscopy by one of the investigators will be asked if they are interested in participating in the study.
The study will be open to all patients undergoing endoscopy that do not have exclusion criteria. We will ask all patients if they are participating in any other studies. If they are participating in any other study then we will ask them for more information to determine whether there could be any harm from participating in both studies and if there is then they will not be enrolled.
Exclusion Criteria:Patients with unstable vital signs will not be included.
Contacts and Locations| United States, California | |
| Stanford University School of Medicine | |
| Stanford, California, United States, 94305 | |
| Principal Investigator: | Shai Friedland | Stanford University |
More Information
No publications provided
| Responsible Party: | Shai Friedland, Stanford University School of Medicine |
| ClinicalTrials.gov Identifier: | NCT01034670 History of Changes |
| Other Study ID Numbers: | SU-06302009-2800, GIIMG0002, 5U54CA105296-03 |
| Study First Received: | November 13, 2009 |
| Last Updated: | February 17, 2011 |
| Health Authority: | United States: Food and Drug Administration United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Neoplasms Gastrointestinal Diseases Digestive System Diseases Stomach Neoplasms Gastrointestinal Stromal Tumors |
Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Stomach Diseases |
ClinicalTrials.gov processed this record on May 19, 2013